Breaking News

Sunshine Biopharma Begins CMO Negotiations

Seeks maker for preclinical studies of breast cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sunshine Biopharma Inc. has initiated negotiations with several CMOs for the GMP manufacture of 1kg of Adva-27a, the company’s lead drug in development for the treatment of breast cancer that has become resistant to current anti-cancer therapies.   The supply of Adva-27a will be used to complete the upcoming animal toxicity studies and plans to file an IND to proceed with the planned Phase I trial. The company intends to make any leftover material available for compassionate-use programs. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters